Terms: = Liver cancer AND NCOA4, RP11-481A12_4, 8031, ENSG00000138293, PTC3, ELE1, Q13772, RFG, DKFZp762E1112, ARA70 AND Prognosis
6065 results:
1. Exploring the role of CDCA4 in liver hepatocellular carcinoma using bioinformatics analysis and experiments.
Liang C; Long K; Zheng W; Zhong R; Li Z; Zhu S; Gu S; Zhu C; Yang Y
Medicine (Baltimore); 2024 May; 103(18):e38028. PubMed ID: 38701314
[TBL] [Abstract] [Full Text] [Related]
2. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract] [Full Text] [Related]
3. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial.
Zeng TM; Jiang TY; Yang G; Cheng Z; Lou C; Wei W; Tao CJ; Hu S; Wang H; Cui XW; Tan YX; Dong LW; Wang HY; Yuan ZG
Clin Transl Med; 2024 May; 14(5):e1675. PubMed ID: 38689424
[TBL] [Abstract] [Full Text] [Related]
4. A retrospective clinical analysis of 11 cases of PEComa from different sites.
Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
[TBL] [Abstract] [Full Text] [Related]
5. Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma.
Zhu JQ; Liu JZ; Yang SW; Ren ZY; Ye XY; Liu Z; Li XL; Han DD; He Q
Front Endocrinol (Lausanne); 2024; 15():1306091. PubMed ID: 38686208
[TBL] [Abstract] [Full Text] [Related]
6. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
[TBL] [Abstract] [Full Text] [Related]
7. Safety and tolerability of OP-724 in patients with haemophilia and liver cirrhosis due to HIV/HCV coinfection: an investigator-initiated, open-label, non-randomised, single-centre, phase I study.
Kimura K; Tanuma J; Kimura M; Imamura J; Yanase M; Ieiri I; Kurosaki M; Watanabe T; Endo T; Yotsuyanagi H; Gatanaga H
BMJ Open Gastroenterol; 2024 Apr; 11(1):. PubMed ID: 38677720
[TBL] [Abstract] [Full Text] [Related]
8. Paraneoplastic Syndromes in Hepatocellular Carcinoma, Epidemiology, and Survival: A Retrospective Seven Years Study.
Burciu C; Sirli R; Bende R; Vuletici D; Miutescu B; Moga T; Bende F; Popescu A; Sporea I; Koppandi O; Miutescu E; Iovanescu D; Danila M
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674198
[No Abstract] [Full Text] [Related]
9. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
Du J; Zhang E; Huang Z
Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
[TBL] [Abstract] [Full Text] [Related]
10. Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma.
Ji Z; Zhang C; Yuan J; He Q; Zhang X; Yang D; Xu N; Chu J
PLoS One; 2024; 19(4):e0298775. PubMed ID: 38662757
[TBL] [Abstract] [Full Text] [Related]
11. A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy.
Li M; Liao J; Wang L; Lv T; Sun Q; Xu Y; Guo Z; Quan M; Qin H; Yu H; Zhang K; Xing W; Yu H
Front Immunol; 2024; 15():1303259. PubMed ID: 38660298
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs.
Wei M; Lu L; Luo Z; Ma J; Wang J
BMC Gastroenterol; 2024 Apr; 24(1):142. PubMed ID: 38654165
[TBL] [Abstract] [Full Text] [Related]
13. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
[TBL] [Abstract] [Full Text] [Related]
14. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
Zhu M; Jin M; Zhao X; Shen S; Chen Y; Xiao H; Wei G; He Q; Li B; Peng Z
BMC Med; 2024 Apr; 22(1):165. PubMed ID: 38637772
[TBL] [Abstract] [Full Text] [Related]
15. An exosome mRNA-related gene risk model to evaluate the tumor microenvironment and predict prognosis in hepatocellular carcinoma.
Du Z; Han X; Zhu L; Li L; Castellano L; Stebbing J; Peng L; Wang Z
BMC Med Genomics; 2024 Apr; 17(1):86. PubMed ID: 38627727
[TBL] [Abstract] [Full Text] [Related]
16. Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy.
Hao X; Xu L; Lan X; Li B; Cai H
BMC Cancer; 2024 Apr; 24(1):475. PubMed ID: 38622578
[TBL] [Abstract] [Full Text] [Related]
17. Fatty Acid Binding Protein 1 is an Independent Prognostic Biomarker for Gallbladder cancer with Direct Hepatic Invasion.
Qiu S; Liu Z; Hu J; Wang Z; Yue Z; Jia Z; Zhang W; Xue Z; Liu Z; Liu Y
Int J Med Sci; 2024; 21(5):862-873. PubMed ID: 38617005
[No Abstract] [Full Text] [Related]
18. Construction and validation of a machine learning-based nomogram to predict the prognosis of HBV associated hepatocellular carcinoma patients with high levels of hepatitis B surface antigen in primary local treatment: a multicenter study.
Xiong Y; Qiao W; Wang Q; Li K; Jin R; Zhang Y
Front Immunol; 2024; 15():1357496. PubMed ID: 38601167
[TBL] [Abstract] [Full Text] [Related]
19. Metastasis patterns and prognosis in young gastric cancer patients: A propensity score‑matched SEER database analysis.
Zhang H; Cheng X; Guo W; Zheng C; Zhang Y; Jing X; Qiao H
PLoS One; 2024; 19(4):e0301834. PubMed ID: 38593111
[TBL] [Abstract] [Full Text] [Related]
20. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
[TBL] [Abstract] [Full Text] [Related]
[Next]
